These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11907381)

  • 1. Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assay.
    Villahermosa ML; Beck I; Pérez-Alvarez L; Contreras G; Frenkel LM; Osmanov S; de Parga EV; Delgado E; Manjon N; Cuevas MT; Thomson MM; Medrano L; Najera R
    J Hum Virol; 2001; 4(5):238-48. PubMed ID: 11907381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors.
    Wallis CL; Mahomed I; Morris L; Chidarikire T; Stevens G; Rekhviashvili N; Stevens W
    J Virol Methods; 2005 May; 125(2):99-109. PubMed ID: 15794978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of the oligonucleotide ligation assay for detection of the M184V drug-resistant mutation in patients infected with human immunodeficiency virus type 1 subtype CRF01_AE.
    Dokuta S; Utaipat U; Praparattanapan J; Keitkarn J; Maneekarn N; Sirisanthana T; Supparatpinyo K
    J Virol Methods; 2013 Jun; 190(1-2):20-8. PubMed ID: 23562659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors: human immunodeficiency virus type 1-infected patients from two geographical areas in Spain. Spanish Groups for Antiretroviral Resistance Studies.
    Pérez-Alvarez L; Villahermosa ML; Cuevas MT; Delgado E; Manjón N; Vázquez de Parga E; Medrano L; Contreras G; Thomson MM; Colomo C; Taboada JA; Nájera R
    J Hum Virol; 2000; 3(3):150-6. PubMed ID: 10881995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.
    Balduin M; Oette M; Däumer MP; Hoffmann D; Pfister HJ; Kaiser R
    J Clin Virol; 2009 May; 45(1):34-8. PubMed ID: 19375978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.
    Van Laethem K; Pannecouque C; Vandamme AM
    Infect Genet Evol; 2007 Sep; 7(5):600-3. PubMed ID: 17567542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates.
    Rezende LF; Prasad VR
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1716-34. PubMed ID: 15183340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors.
    Villahermosa ML; Contreras G; Pérez-Alvarez L; Bru F; Medrano L; Delgado E; Colomo C; Thomson M; Nájera R
    Antivir Ther; 1998; 3(4):221-7. PubMed ID: 10682142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J; Yue J; Wu S; Yan Y
    Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.
    de Mendoza C; Jiménez-Nacher I; Garrido C; Barreiro P; Poveda E; Corral A; Zahonero N; González-Lahoz J; Soriano V
    Clin Infect Dis; 2008 Jun; 46(11):1782-5. PubMed ID: 18426370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
    Prado JG; Franco S; Matamoros T; Ruiz L; Clotet B; Menéndez-Arias L; Martínez MA; Martinez-Picado J
    Virology; 2004 Aug; 326(1):103-12. PubMed ID: 15262499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates.
    Tsongalis GJ; Gleeson T; Rodina M; Anamani D; Ross J; Joanisse I; Tanimoto L; Ziermann R
    J Clin Virol; 2005 Dec; 34(4):268-71. PubMed ID: 16286050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
    Hachiya A; Gatanaga H; Kodama E; Ikeuchi M; Matsuoka M; Harada S; Mitsuya H; Kimura S; Oka S
    Virology; 2004 Oct; 327(2):215-24. PubMed ID: 15351209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The V118I mutation as a marker of advanced HIV infection and disease progression.
    Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
    Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
    Parkin NT; Gupta S; Chappey C; Petropoulos CJ
    Antimicrob Agents Chemother; 2006 Jan; 50(1):351-4. PubMed ID: 16377709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.